Abstract
Purpose
To analyse the long anatomical and functional outcome of a subgroup of the DICAT II study cohort, consisting of 26 patients undergoing cataract surgery and withdrawn from the study for a clinically significant worsening of early diabetic macular edema (DME).Materials
Patients who underwent cataract surgery and withdrawn from the DICAT II study for a clinically significant worsening of early DME with at least 12 months follow-up after the dropout. The study population was divided into two groups according to the clinical evaluation at one-year follow-up: ongoing treatment patients for DME (Treatment group, TG) and patients no longer treated (Non Treatment group, NTG).Results
Central foveal thickness (CFT) at baseline and dropout time were higher in TG than in the NTG, with a statistically significant difference (p < 0.05). In addition, TG patients reported a higher levels of glycated hemoglobin at time baseline compared to NTG patients (7.81 ± 1.15 vs 7.02 ± 0.56; p = 0.048). The linear regression analysis demonstrated a statistically significant relationship between the visual acuity and the ongoing treatment group at one-year follow-up (p = 0.042).Conclusion
The study provides parameters to be considered when assessing the risk of developing persistent DME after cataract surgery in diabetic patients. In particular, CFT at baseline and dropout time have been reported to be an effective and predictable OCT biomarkers when evaluating DME progression. During the evaluation of the systemic disease, similar results were found for the glycated hemoglobin at baseline.Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Central retinal thickness assessment in a real life setting after cataract surgery in diabetic patients.
J Fr Ophtalmol, 41(10):904-909, 22 Nov 2018
Cited by: 3 articles | PMID: 30470488
Outcomes of Patients With Active Diabetic Macular Edema at the Time of Cataract Surgery Managed With Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
Am J Ophthalmol, 229:194-199, 20 Apr 2021
Cited by: 5 articles | PMID: 33852907
Intravitreal dexamethasone implant one month before versus concomitant with cataract surgery in patients with diabetic macular oedema: the dexcat study.
Acta Ophthalmol, 99(1):e74-e80, 26 Jun 2020
Cited by: 11 articles | PMID: 32588978
Optimizing treatment for diabetic macular edema during cataract surgery.
Front Endocrinol (Lausanne), 14:1106706, 25 Jan 2023
Cited by: 4 articles | PMID: 36761187 | PMCID: PMC9905225
Review Free full text in Europe PMC